← SynDRA
REBASTINIB
SynDRA canonical compound SYN0026646 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | TEK |
|---|
| Mechanism of action | TIE tyrosine kinase inhibitor |
|---|
All known targets
- ABL1
- TEK
- BCR
- FLT3
- KDR
- FGR
- HCK
- LYN
- SRC
- YES1
Mechanisms of action (all sources)
- VEGFR inhibitor
- Abl kinase inhibitor
- TIE tyrosine kinase inhibitor
- ABL1 INHIBITOR
- Tyrosine-protein kinase ABL inhibitor
- YES1 INHIBITOR
- Bcr-Abl kinase inhibitor
- ABL1 MODULATOR
- TEK INHIBITOR
Drug classes
- Antineoplastic Agents
- Protein Kinase Inhibitors
Cross-references
Synonyms
- Dcc-2036
- DCC-2036 FREE BASE
- Dp-1919
- DCC 2036
- DCC-2036 (Rebastinib)
- CHEBI:62166
- UNII-75017Q6I97
- Rebastinib(DCC-2036)
- 4-(4-(3-(3-(tert-butyl)-1-(quinolin-6-yl)-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)-N-methylpicolinamide
- DCC2036
- DP-1919
- 4-[4-({[3-Tert-Butyl-1-(Quinolin-6-Yl)-1h-Pyrazol-5-Yl]carbamoyl}amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
- 75017Q6I97
- 4-[4-[(5-Tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide,4-methylbenzenesulfonic acid;4-[4-[(
- DP 1919
- rebastinibum
- RefChem:930592
- DTXCID8067024
- MFCD19443646
- Rebastinib [USAN]
- Rebastinib (USAN)
- Rebastinib [USAN:INN]
- C30H28FN7O3
- 3qri
- 3qrj
- REBASTINIB [INN]
- DCC-2036; Rebastinib
- REBASTINIB [WHO-DD]
- MLS006011270
- DCC-2036 (Rebastinib)?
- GTPL9173
- orb1305227
- SCHEMBL2034290
- SCHEMBL29354367
- SCHEMBL29733447
- SCHEMBL30499050
- BDBM185674
Look up REBASTINIB in the interactive SynDRA portal →